Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease. Peer-reviewed case study commissioned by the SACGHS Read more about Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease. Peer-reviewed case study commissioned by the SACGHS
Access—or not—in academic biomedical research Read more about Access—or not—in academic biomedical research
Impact of gene patents and licensing practices on access to genetic testing for hereditary hemochromatosis. Peer-reviewed case study commissioned by the SACGHS Read more about Impact of gene patents and licensing practices on access to genetic testing for hereditary hemochromatosis. Peer-reviewed case study commissioned by the SACGHS
Do recent US Supreme Court rulings on patenting of genes and genetic diagnosis affect the practice of genetic screening and diagnosis in prenatal and reproductive care? Read more about Do recent US Supreme Court rulings on patenting of genes and genetic diagnosis affect the practice of genetic screening and diagnosis in prenatal and reproductive care?
Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis. Peer-reviewed case study commissioned by the SACGHS Read more about Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis. Peer-reviewed case study commissioned by the SACGHS
Impact of gene patents and licensing practices on access to genetic testing for hearing loss. Peer-reviewed case study commissioned by the SACGHS Read more about Impact of gene patents and licensing practices on access to genetic testing for hearing loss. Peer-reviewed case study commissioned by the SACGHS
Gene patents and personalized medicine – what lies ahead? Read more about Gene patents and personalized medicine – what lies ahead?
Reflections on the cost of “low-cost” whole genome sequencing: Framing the health policy debate Read more about Reflections on the cost of “low-cost” whole genome sequencing: Framing the health policy debate
Harm, hype and evidence: ELSI research and policy guidance Read more about Harm, hype and evidence: ELSI research and policy guidance
The mouse that trolled: The long and tortuous history of a gene mutation patent that became an expensive impediment to Alzheimer’s research Read more about The mouse that trolled: The long and tortuous history of a gene mutation patent that became an expensive impediment to Alzheimer’s research
